(0.10%) 5 105.06 points
(0.24%) 38 332 points
(0.14%) 15 950 points
(-1.43%) $82.65
(5.77%) $2.03
(0.23%) $2 352.60
(-0.16%) $27.49
(3.84%) $957.55
(-0.22%) $0.933
(-0.33%) $10.99
(-0.53%) $0.796
(1.65%) $93.39
7.63% $ 1.970
Live Chart Being Loaded With Signals
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe...
Stats | |
---|---|
Tagesvolumen | 5 649.00 |
Durchschnittsvolumen | 98 766.00 |
Marktkapitalisierung | 15.05M |
EPS | $0 ( 2024-03-28 ) |
Nächstes Ertragsdatum | ( $-0.600 ) 2024-07-04 |
Last Dividend | $0.220 ( 2015-06-05 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.400 |
ATR14 | $0.0230 (1.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2004-02-13 | Robert R Mccormick Tribune Foundation | Sell | 65 200 | Common Stock |
2004-02-17 | Robert R Mccormick Tribune Foundation | Sell | 92 000 | Common Stock |
2004-02-18 | Robert R Mccormick Tribune Foundation | Sell | 17 800 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 3 transactions |
Buy: 0 | Sell: 175 000 |
Trinity Biotech PLC Korrelation
10 Am meisten positiv korreliert | |
---|---|
GRCL | 0.905 |
NETE | 0.9 |
JOAN | 0.895 |
RXT | 0.886 |
CUTR | 0.885 |
VNDA | 0.88 |
KPTI | 0.88 |
UDMY | 0.88 |
PTPI | 0.878 |
POTX | 0.878 |
10 Am meisten negativ korreliert | |
---|---|
SVAC | -0.899 |
AUPH | -0.891 |
USCR | -0.88 |
RARE | -0.879 |
PAIC | -0.877 |
MLVF | -0.866 |
EZGO | -0.865 |
SUMR | -0.863 |
AMYT | -0.861 |
IIN | -0.859 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Trinity Biotech PLC Finanzdaten
Annual | 2023 |
Umsatz: | $56.83M |
Bruttogewinn: | $18.50M (32.56 %) |
EPS: | $-15.69 |
FY | 2023 |
Umsatz: | $56.83M |
Bruttogewinn: | $18.50M (32.56 %) |
EPS: | $-15.69 |
FY | 2022 |
Umsatz: | $74.78M |
Bruttogewinn: | $22.05M (29.48 %) |
EPS: | $-6.08 |
FY | 2021 |
Umsatz: | $92.97M |
Bruttogewinn: | $38.08M (40.96 %) |
EPS: | $0.0400 |
Financial Reports:
No articles found.
Trinity Biotech PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.400 | 2011-06-07 |
Last Dividend | $0.220 | 2015-06-05 |
Next Dividend | $0 | N/A |
Payout Date | 2015-07-01 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $1.190 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.55 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0.400 | 4.67% |
2012 | $0.150 | 1.49% |
2013 | $0.200 | 1.36% |
2014 | $0.220 | 0.88% |
2015 | $0.220 | 1.21% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.431 | 1.500 | -8.63 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.412 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 1.650 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.60 | 0.800 | 2.02 | 1.613 | [1 - 3] |
quickRatioTTM | 1.271 | 0.800 | 7.23 | 5.78 | [0.8 - 2.5] |
cashRatioTTM | 0.245 | 1.500 | 9.75 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.923 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -2.41 | 1.000 | -2.00 | -2.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -8.33 | 2.00 | -2.78 | -5.55 | [0 - 30] |
freeCashFlowPerShareTTM | -10.09 | 2.00 | -5.05 | -10.00 | [0 - 20] |
debtEquityRatioTTM | -2.29 | -1.500 | -9.16 | 10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.334 | 1.000 | 7.76 | 7.76 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.471 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.233 | 1.000 | -2.40 | -2.40 | [0.2 - 2] |
assetTurnoverTTM | 0.956 | 0.800 | 6.96 | 5.57 | [0.5 - 2] |
Total Score | -1.023 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.114 | 1.000 | -0.113 | 0 | [1 - 100] |
returnOnEquityTTM | 1.650 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -10.09 | 2.00 | -3.36 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -8.33 | 2.00 | -2.78 | -5.55 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00148 | 1.500 | -3.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.225 | 1.000 | -8.12 | 0 | [0.1 - 0.5] |
Total Score | -1.549 |
Trinity Biotech PLC
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.